|
|
|
|
|
|
Sponsored by: |
Advanced Life Sciences, Inc. |
Information provided by: | Advanced Life Sciences, Inc. |
ClinicalTrials.gov Identifier: | NCT00336544 |
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
Condition | Intervention | Phase |
Pneumonia |
Drug: Cethromycin Drug: Clarithromycin |
Phase III |
MedlinePlus related topics: | Pneumonia |
ChemIDplus related topics: | Clarithromycin Cethromycin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults |
Estimated Enrollment: | 500 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | December 2006 |
Lower respiratory tract infections remain one of the leading causes of death worldwide. Increasing rates of antibiotic resistance and newer, more pervasive pneumonia-causative pathogens contribute to this statistic. Currently available macrolide antibiotics for the treatment of community-acquired pneumonia are slowly losing effectiveness, resulting in the need to develop newer drugs to fight resistant infections. In this study, we compare the safety and efficacy of a common macrolide, clarithromycin, to a new ketolide, cethromycin.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |||||
ARGENTINA - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
CHILE - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
PERU - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
BULGARIA - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
CROATIA - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
ESTONIA - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
UKRAINE - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
HUNGARY - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
ISRAEL - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
POLAND - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
ROMANIA - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
THE NETHERLANDS - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 | |||||
GERMANY - Advanced Life Sciences | |||||
Woodridge, Illinois, United States, 60517 |
Advanced Life Sciences, Inc. |
Study Director: | David A. Eiznhamer, PhD. | Advanced Life Sciences |
Study ID Numbers: | CL06-001 |
First Received: | June 9, 2006 |
Last Updated: | March 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00336544 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|